Connor Clark & Lunn Investment Management Ltd. Buys Shares of 95,381 Elanco Animal Health Incorporated $ELAN

Connor Clark & Lunn Investment Management Ltd. bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 95,381 shares of the company’s stock, valued at approximately $2,347,000.

Several other hedge funds also recently modified their holdings of the business. NewEdge Advisors LLC raised its holdings in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Elanco Animal Health in the second quarter worth $38,000. Root Financial Partners LLC boosted its holdings in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health during the fourth quarter worth $41,000. Finally, Torren Management LLC acquired a new position in Elanco Animal Health during the fourth quarter worth $46,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 1.3%

ELAN stock opened at $24.16 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health Incorporated has a 52-week low of $17.11 and a 52-week high of $27.98. The company has a 50-day moving average of $24.62 and a two-hundred day moving average of $24.01. The stock has a market capitalization of $12.07 billion, a price-to-earnings ratio of -58.93, a price-to-earnings-growth ratio of 1.47 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same period in the previous year, the company posted $0.26 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, equities research analysts anticipate that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ELAN. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. UBS Group increased their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. JPMorgan Chase & Co. increased their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Weiss Ratings downgraded Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 20th. Finally, TD Cowen upped their target price on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average target price of $29.09.

Insider Activity at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius acquired 40,000 shares of the stock in a transaction dated Thursday, August 20th. The shares were acquired at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the purchase, the director owned 188,647 shares in the company, valued at approximately $4,414,339.80. The trade was a 26.91% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Robert M. Vanhimbergen bought 4,200 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $23.08 per share, for a total transaction of $96,936.00. Following the transaction, the chief financial officer directly owned 137,516 shares of the company’s stock, valued at $3,173,869.28. This trade represents a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 63,198 shares of company stock valued at $1,473,109. 1.14% of the stock is owned by corporate insiders.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.